A novel method to assess platelet inhibition by eptifibatide with thrombelastograph®

Anesthesia and Analgesia

Volumn 99, Issue 6, 2004, Pages 1794-1799

  Katori, Nobuyuki ^a   Szlam, Fania ^a   Levy, Jerrold H ^a   Tanaka, Kenichi A ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; BATROXOBIN; CITRIC ACID; EPTIFIBATIDE; HEPARIN; KAOLIN;

ANTICOAGULATION; ARTICLE; BLEEDING; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; DRUG MONITORING; HUMAN; INTERMETHOD COMPARISON; NORMAL HUMAN; PRIORITY JOURNAL; TECHNIQUE; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE TRANSFUSION; THROMBOELASTOGRAPHY;

ADENOSINE DIPHOSPHATE; ANTICOAGULANTS; BATROXOBIN; BLOOD VISCOSITY; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; KAOLIN; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; THROMBELASTOGRAPHY;

EID: 9244240822     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/01.ANE.0000136476.82598.88     Document Type: Article

References (23)

1. Mousa SA, Bozarth JM, Forsythe MS, Slee A. Differential antiplatelet efficacy for various GPIIb/IIIa antagonists: role of plasma calcium levels. Cardiovasc Res 2000;47:819-26.
2. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-96.
3. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade: evaluation of platelet IIb/IIIa inhibitor for stenting. Lancet 1998;352:87-92.
4. Gammie JS, Zenati M, Kormos RL, et al. Abciximab and excessive bleeding in patients undergoing emergency cardiac operations. Ann Thorac Surg 1998;65:465-9.
5. Steinhubl SR, Talley JD, Braden GA, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 2001;103:2572-8.
6. Khurana S, Mattson JC, Westley S, et al. Monitoring platelet glycoprotein IIb/IIIa-fibrin interaction with tissue factor-activated thromboelastography. J Lab Clin Med 1997;130. 401-11.
7. Waters JH, Anthony DG, Gottlieb A, Sprung J. Bleeding in a patient receiving platelet aggregation inhibitors. Anesth Analg 2001;93:878-82.
8. Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 2003;107:32-7.
9. Glidden PF, Malaska C, Herring SW. Thromboelastograph assay for measuring the mechanical strength of fibrin sealant clots. Clin Appl Thromb Hemost 2000;6:226-33.
10. Covic L, Singh C, Smith H, Kuliopulos A. Role of the PAR4 thrombin receptor in stabilizing platelet-platelet aggregates as revealed by a patient with Hermansky-Pudlak syndrome. Thromb Haemost 2002;87:722-7.
11. Yende S, Wunderink RG. Effect of clopidogrel on bleeding after coronary artery bypass surgery. Crit Care Med 2001;29:2271-5.
12. Oshita K, Az-ma T, Osawa Y, Yuge O. Quantitative measurement of thromboelastography as a function of platelet count. Anesth Analg 1999;89:296-9.
13. Tcheng JE, Talley JD, O'Shea JC, et al. Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study). Am J Cardiol 2001;88:1097-102.
14. ++ accounts for the sex difference in the aggregation of human platelets in citrated platelet-rich plasma. Thromb Res 1990; 58:47-60.
15. Marguerie GA, Edgington TS, Plow EF. Interaction of fibrinogen with its platelet receptor as part of a multistep reaction in ADP-induced platelet aggregation. J Biol Chem 1980;255: 154-61.
16. Leino L, Sorvajarvi K. CD11b is a calcium-dependent epitope in human neutrophils. Biochem Biophys Res Commun 1992;187: 195-200.
17. Hongo RH, Brent BN. Association of eptifibatide and acute profound thrombocytopenia. Am J Cardiol 2001;88:428-31.
18. Tanaka KA, Vega JD, Kelly AB, et al. Eptifibatide-induced thrombocytopenia and coronary bypass operation. J Thromb Haemost 2003;1:392-4.
19. Dascombe WH, Dumanian G, Hong C, et al. Application of thrombin based fibrin glue and non-thrombin based batroxobin glue on intact human blood vessels: evidence for transmural thrombin activity. Thromb Haemost 1997;78:947-51.
20. Gilchrist IC, O'Shea JC, Kosoglou T, et al. Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention. Circulation 2001;104:406-11.
21. Mousa SA, Khurana S, Forsythe MS. Comparative in vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists on platelet-mediated clot strength induced by tissue factor with use of thromboelastography: differentiation among glycoprotein IIb/IIIa antagonists. Arterioscler Thromb Vasc Biol 2000;20:1162-7.
22. Gawaz M, Ruf A, Pogatsa-Murray G, et al. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors. Thromb Haemost 2000;83:915-22.
23. Honda S, Tomiyama Y, Pampori N, et al. Ligand binding to integrin alpha(v)beta(3) requires tyrosine 178 in the alpha(v) subunit. Blood 2001;97:175-82.